Beyond Peptides: Advancing Radio-DARPin Therapeutics from Platform Innovation to Clinical Proof-of- Concept
1:30 pm - Thursday 3rd December 2026
- Presenting imaging and dosimetry insights from MP0712, a DLL3-targeted Pb-212 Radio-DARPin Therapeutic currently in Phase I development
- Exploring how half-life extended Radio-DARPins are designed to overcome the limitations of conventional peptide-based radiopharmaceutical approaches for challenging targets
- Sharing key learnings from advancing a novel targeted alpha therapy approach across clinical and preclinical development programmes